Braingaze in the news

Braingaze raises €1.5 milion to improve cognitive health

Braingaze has closed a €1.5 million financing round that will allow it to accelerate the clinical and business development of its diagnostic and therapeutic solutions for cognitive disorders and neurodegenerative diseases such as autism, ADHD and Alzheimer's disease. 7 March 2024 by Expansión

New innovative health technology fund aims to invest with impact

A new health innovation fund is investing in health and care technologies and innovations to transform the current health and social care system, including improving access to and quality of care. The Special Opportunities Fund is starting with Braingaze, a revolutionary new tool that uses eye tracking to help diagnose ADHD in a matter of minutes. The tool enables drug-free cognitive disorders treatment and brings brain-related healthcare into the digital and AI-powered age. March 7, 2024 by Charity Today (link).

Braingaze raises 1.5 million to develop cognitive health solutions

Braingaze leadership expresses their pride to have raised €1.5 million to advance the development and international market launch of solutions to improve cognitive health. The funds will be used to further develop innovative technologies to address challenges in the early detection and management of neuropsychiatric disorders such as ADHD. 6 March 2024 by El Referente (link)

RYSE digital health fund makes its first investment

UK healthcare investor RYSE Asset Management has closed a new fund to support start-ups involved in digital health and care technologies, raising $50 million.

The new Special Opportunities Fund will be available to groups requiring seed or first-round financing and will focus on those developing “digital diagnostics, digital therapeutics, and medical devices that will help solve the challenges facing the NHS and other health and care delivery systems globally.”

The first recipient of the new fund has also been announced – Spanish digital detection and treatment healthtech company Braingaze – which was set up to develop apps that can be used to support and treat conditions like attention deficit hyperactivity disorder (ADHD), autism spectral disorder (ASD), and dyslexia in children, and detect Alzheimer’s disease and mild cognitive impairment (MCI) in adults. March 5th, 2024 by pharmaphorum (link)

DTx Consortium and Vodafone Business will drive the adoption of digital therapies in Spain

The DTx Consortium and Vodafone Business will collaborate to promote the use of digital therapies in Spain. This agreement aims to promote access to innovative digital treatments to improve the health of the population. Vodafone Business will provide its infrastructure and technology to support the implementation and distribution of these therapies, thus facilitating their adoption nationwide. 18 May 2023 by Portaltic (link)

Braingaze is a finalist for the 2021 Greenhouse Accelerator

PepsiCo, a leading food and beverage company, selected 10 finalists for its start-up acceleration program, which focuses on driving innovation and development of emerging companies in areas such as sustainability, wellness and nutrition. The finalists, including Braingaze, represent a variety of industries, from food and beverage to technology and sustainability. 11 January 2021 by Forbes (link)